NCT02507375View on ClinicalTrials.gov

A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Erlotinib

Erlotinib will be administered as oral tablets.

DRUG

Pertuzumab

Pertuzumab will be administered as intravenous (IV) infusion.

Trial Locations (3)

2020

Antwerp

08035

Barcelona

M20 4BX

Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02507375 - A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter